---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-039052"
form_type: "8-K"
ticker: "KYNB"
cik: "0000921299"
company_name: "KYNTRA BIO, INC."
filed_at: "2023-08-07T23:59:59+00:00"
generated_at: "2026-06-12T05:27:40.382715+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# FibroGen Q2 revenue up 49% but net loss widens; multiple Phase 3 failures; new CEO appointed

## Summary
- Q2 total revenue $44.3M (+49% YoY); net loss $87.7M ($0.90) vs $72.6M ($0.78) last year; includes $24.6M one-time charge.
- Reported negative topline from three Phase 3 trials: MATTERHORN (roxadustat MDS), LELANTOS-1 (pamrevlumab DMD), ZEPHYRUS-1 (pamrevlumab IPF); ZEPHYRUS-2 discontinued.
- China roxadustat net sales $76.4M (+44% YoY) driven by >40% volume growth; number one anemia brand in China.
- Appointed Thane Wettig as Interim CEO; implemented cost reduction plan targeting $100-120M annualized GAAP expense savings.
- Exclusive license for FOR46 (FG-3246) ADC targeting CD46 for mCRPC; $75M non-dilutive term loan from Morgan Stanley.

## SEC filing metadata
- accession: 0000950170-23-039052
- form_type: 8-K
- ticker: KYNB
- cik: 0000921299
- company_name: KYNTRA BIO, INC.
- filed_at: 2023-08-07T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/921299/000095017023039052/0000950170-23-039052-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/921299/000095017023039052/fgen-20230807.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-039052
- JSON: https://secwatch.observer/filing/0000950170-23-039052.json
- Plain text: https://secwatch.observer/filing/0000950170-23-039052.txt

## Key facts
- Earnings Releases
  KYNTRA BIO, INC. reported second quarter 2023 results: revenue $44.3 million, net income $87.7 million, EPS $0.90 net loss per basic and diluted share.
  - Period: second quarter 2023
  - Revenue: $44.3 million
  - Net income: $87.7 million
  - EPS: $0.90 net loss per basic and diluted share
  - Result: reported results
  source text: the filing of two INDs: FG-3165 (anti-Gal9 antibody) in 1Q 2024 and FG-3175 (anti-CCR8 antibody) in 2H 2024. Financial: • Total revenue for the second quarter of 2023 was $44.3 million, as compared to $29.8 million for the second quarter of 2022, an increase of 49%. • Net loss for the second quarter of 2023 was $87.7 million, or $0.90 net loss per basic and
  evidence_url: https://www.sec.gov/Archives/edgar/data/921299/000095017023039052/0000950170-23-039052-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.